Miloš Mitrović

Dr. Miloš Mitrović

Clinical Department fro Renal Diseases, University Medical Cnter Zvezdara, School of Medicine, University of Belgrade
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Journal of Renal Nutrition
Verified
Journal Article
Open access
MMMiloš Mitrović
Miloš Mitrović
VSVerica Stanković-Popović
Verica Stanković-Popović
MTMaja Tolinacki
Maja Tolinacki
NGNataša Golić
Nataša Golić
SBSvetlana Soković Bajić
Svetlana Soković Bajić
NDNada Dimković
Nada Dimković
Altering dysbiotic gut flora through synbiotic supplementation has recently been recognized as a potential treatment strategy to reduce the levels of gut-derived uremic toxins and decrease inflammation. Assessing its efficacy and safety has been the main goal of our randomized, double-blind, placebo-controlled study. A total of 34 nondialyzed chronic kidney disease patients, aged ≥18 years, with an estimated glomerular filtration rate between 15 and 45 mL/minute, were randomized either to an intervention group (n = 17), receiving synbiotic (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin), or control group (n = 17), receiving placebo during 12 weeks. The impact of treatment on the dynamic of serum levels of gut-derived uremic toxins, total serum indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide, was defined as the primary outcome of the study. Secondary outcomes included changes in the stool microbiome, serum interleukin-6 levels, high-sensitivity C-reactive protein, estimated glomerular filtration rate, albuminuria, diet, gastrointestinal symptom dynamics, and safety. Serum levels of uremic toxins were determined using ultraperformance liquid chromatography. The stool microbiome analysis was performed using the 16S ribosomal ribonucleic acid gene sequencing approach. Synbiotic treatment significantly modified gut microbiome with Bifidobacteria, Lactobacillus, and Subdoligranulum genera enrichment and consequently reduced serum level of indoxyl sulfate (ΔIS -21.5% vs. 5.3%, P < .001), improved estimated glomerular filtration rate (ΔeGFR 12% vs. 8%, P = .029), and decreased level of high-sensitivity C-reactive protein (-39.5 vs. -8.5%, P < .001) in treated patients. Two patients of the intervention arm complained of increased flatulence. No other safety issues were noted. Synbiotics could be available, safe, and an effective therapeutic strategy we could use in daily practice in order to decrease levels of uremic toxins and microinflammation in chronic kidney disease patients.

7 February 2024 in Romanian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MMMiloš Mitrović
Miloš Mitrović
ADAna Dobrosavljević
Ana Dobrosavljević
OOOlga Odanović
Olga Odanović
TKTamara Knežević-Ivanovski
Tamara Knežević-Ivanovski
ĐKĐorđe Kralj
Đorđe Kralj
VSVerica Stanković-Popović
Verica Stanković-Popović
Introduction: Metabolic Dysfunction-associated Liver Disease (MASLD) represents a spectrum of conditions from simple fat accumulation to non-alcoholic steatohepatitis. The possible role of the intestinal microbiome on MASLD development has been in focus. Our study aimed to examine the effects of synbiotics on the liver steatosis, inflammation, and stool microbiome. Methods: A double-blind, placebo-controlled study was conducted involving 84 MASLD patients, defined by an elastometric attenuation coefficient (ATT) greater than 0.63 dB/cm/MHz with an alanine aminotransferase level above 40 U/L for men and 35 U/L for women. The patients were divided into an intervention group treated with a synbiotic with 64x109 CFU of Lactobacillus and Bifidobacterium and 6.4g of inulin and a control group treated with a placebo. Results: Using synbiotics for 12 weeks significantly decreased liver steatosis (ΔATT -0.006±0.023 vs -0.016±0.021 dB/cm/MHz, p=0.046). The group of patients treated with synbiotics showed a significant decrease in the level of high-sensitive C-reactive protein (Δhs-CRP 0 vs -0.7 mg/L, p≤0.001). Synbiotics enriched the microbiome of patients in the intervention group with the genera Lactobacillus, Bifidobacterium, Faecalibacterium, and Streptococcus, by 81%, 55%, 51%, and 40%, respectively, with a reduction of Ruminococcus and Enterobacterium by 35% and 40%. Synbiotic treatment significantly shortened the gut transition time (ΔGTT -5h vs. -10h, p=0.031). Conclusion: Synbiotics could be an effective and safe option that could have place in MASLD treatment.

Verified
Journal Article
Open access
PDF file
SESanja Erceg
Sanja Erceg
JMJelena Munjas
Jelena Munjas
Miron SopicMiron Sopic
Miron Sopic
RTRatko S. Tomasevic
Ratko S. Tomasevic
MMMiloš Mitrović
Miloš Mitrović
ANAna Ninic
Ana Ninic
Metabolic dysfunction-associated steatotic liver disease (MASLD), a hepatic form of metabolic syndrome, often co-occurs with type 2 diabetes (T2D) and now affects approximately 30% of the global population. MASLD encompasses conditions from simple steatosis to metabolic dysfunction-associated steatohepatitis, with oxidative stress (OS) driving progression through inflammation. This study analyzes the expression levels of circulating miRNAs and redox status markers in MASLD patients with and without T2D, exploring their potential as disease biomarkers. The expressions of miR-21, miR-34a, and miR-122 were analyzed in the platelet-poor plasma of 147 participants, divided into three groups: MASLD + T2D (48), MASLD (50), and a control group (49). Total oxidant status (TOS), total antioxidant status (TAS), ischemia-modified albumin (IMA), and superoxide anion radical (O2•−) were measured in serum and plasma. Logistic regression showed that miR-21, miR-34a, TOS, TAS, O2•−, and IMA were positive predictors of MASLD, while miR-21 and TAS were negative predictors of T2D in MASLD. Although miR-122 did not show a significant association with either condition, in combination with miR-34a and other markers such as lipid status and liver enzymes, a new significant predictor of MASLD was identified. Circulating miRNAs in combination with redox status markers, lipid status and liver enzymes show potential as MASLD biomarkers.

22 March 2017 in CEN Case Reports
Verified
Journal Article
Closed access
PDF file
MMMiloš Mitrović
Miloš Mitrović
PĐP. Đurić
P. Đurić
AJA. Janković
A. Janković
VSVerica Todorov Sakić
Verica Todorov Sakić
JTJ. Tošić-Dragović
J. Tošić-Dragović
NDN. Dimković
N. Dimković

2 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMiloš Mitrović
Miloš Mitrović
SSStanković-Popović Stanković-Popović
Stanković-Popović Stanković-Popović
SESanja Erceg
Sanja Erceg
MMMilena Perisic Mitrovic
Milena Perisic Mitrovic
ADAna Dobrosavljević
Ana Dobrosavljević
PSPetar Svorcan
Petar Svorcan
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of chronic liver disease and is closely associated with metabolic ab-normalities and cardiovascular risks. Butyrate, a short-chain fatty acid produced by gut microbiota, has the potential to enhance liver health by modulating inflammation and supporting gut barrier integrity. This study aimed to investigate and compare the effects of sodium butyrate and calcium butyrate in patients with MASLD. Methods: In this single-center, randomized clinical trial, 181 patients with MASLD were enrolled and assigned to receive either sodium butyrate (n=121) or calcium butyrate (n=60) supplementation at a daily dose of 1000 mg. The primary endpoint was the change in liver steatosis, measured using the Controlled Attenuation Parameter (CAP) via Fi-broScan®. Secondary endpoints included liver stiffness, biochemical parameters, se-rum and fecal calprotectin levels, stool short-chain fatty acid levels, and microbiome composition. A subgroup analysis compared responders (a ≥5% reduction in CAP) to non-responders. Results: There were no significant changes in CAP values for either group (ΔCAP: sodium butyrate, 0.84; calcium butyrate, –0.23; p=0.70). Sodium butyrate significantly reduced serum trimethylamine N-oxide, while calcium butyrate led to a decrease in fecal calprotectin levels. Responders demonstrated a lower body mass in-dex, higher levels of high-sensitivity C-reactive protein and HbA1c, and distinct mi-crobiome profiles, characterized by lower abundance of Subdoligranulum and higher abundance of Catenibacterium. Conclusions: Although butyrate supplementation did not significantly improve liver steatosis as measured by CAP, the differing effects on metabolic and inflammatory markers suggest that there may be potential benefits for specific subgroups of patients with MASLD.

25 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
IFIrena Franković
Irena Franković
IDIvana Djuricic
Ivana Djuricic
ANAna Ninic
Ana Ninic
JVJelena Vekic
Jelena Vekic
TVTara Vorkapić
Tara Vorkapić
AZAleksandra Zeljkovic
Aleksandra Zeljkovic
The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) underscores the need for better understanding of its complex pathogenesis. Lipid accumulation in hepatocytes is among principal mechanisms contributing to MASLD development. While routine lipid parameters are well studied, the profile of circulating fatty acids in MASLD patients remains less explored. This study aimed to assess relative proportions of individual fatty acids in plasma of MASLD patients and to explore their associations with other biochemical markers of MASLD. Ninety-one patients and 48 healthy individuals were enrolled. The relative proportions of fatty acids in plasma were determined using gas chromatography with FID detection. Proportions of total n-6 polyunsaturated fatty acids (PUFAs) and linoleic acid (LA) in plasma were lower in MASLD patients (p = 0.001 and p = 0.004, respectively), with no differences observed in n-3 PUFAs. Total plasma n-6 PUFAs correlated negatively with body mass index, hepatic steatosis indices, triglyceride concentration and coronary risk index. Decreased prevalence of n-6 PUFAs in plasma was independently associated with higher odds of MASLD (OR = 0.769; CI: 0.611–0.968; p = 0.025). Our findings indicate an altered circulatory fatty acid distribution in MASLD, characterized by a reduced amount of n-6 PUFAs, particularly LA, which may have significant implications for the prevention and treatment of MASLD.